Cell Cycle, Apoptosis, Cancer Flashcards
Cell types
Permanent - remain in Go, cannot be regenerated
*cardiac muscle, neurons, RBCs
Stable (quiescent) - in Go, but can re-enter cycle at G1 if GFs are present
*hepatocytes, epithelium of kidney -> Regeneration of damaged tissue
Labile - never enter Go, always replicating
*gut epithelium, skin, hair follicles, bone marrow
Which stage is CDK 4 and CDK 6 active and what cyclin binds to it?
beginning of Go
Mitogen (growth factor) dependent
Activated by cyclin D
During which phase is CDK2 active and what cyclin binds it?
End of G1
Mitogen independent
Bound by cyclin E
During which please is CDK1 and CDK2 active and what cyclin binds it?
S phase
bound by cyclin A
During which phase is CDK1 active and which cyclin binds it?
G2 phase
Bound by Cyclin B
Pathway to proceed past G1 checkpoint
Mitogen/growth factor present RAS pathway MAPK -> enter nucleus Expression of Myc (gene regulating ptn) Increased CYCLIN D concentration Binds CDK 4,6 Phosphorylation of RB -> released EF2 Cell cycle progression
Apoptosis - Extrinsic pathway
Death signal from outside of the cell (tumor necrosis factor, FAS ligand)
Receptor recruits pro-caspases 8 & 10
Pro-caspases are cleaved/activated -> caspases 8 & 10 (“initiators”)
Activate Caspases 3 & 7 (“executioners”)
Apoptosis
How are the extrinsic and intrinsic apoptosis pathways linked?
Caspase 8 —>
Activates Death domain protein (BID) —>
Activates BAX and BAK —>
Cause mito to release cytochrome C
Apoptosis intrinsic pathway
Intrinsic stimuli (DNA damage, ER stress, hypoxia, metabolic stress)
Activates BAX and BAK
mito —> release cytochrome C —> cytosol
Activates apoptosis peptidase activating factor (Apaf1)
Apoptosome forms
Activates Caspase 9
Activates Caspase 3 & 7 (“executioners”)
Apoptosis
How is RAS related to cancer?
RTK -> RAS pathway
RAS mutation (glycine -> valine) —> RAS pathway always ON
* oncogenic
* gain of function mutation
Which pathway mutation results in glioblastomas?
Deletion in EDF receptor
- type of receptor tyrosine kinase (RTK)
- oncogenic
- gain of function mutation
- pathways is ALWAYS ON
Which pathway mutation results in breast cancer (HER2)?
HER2 is a RTK
Valine -> glutamate mutation in HER2 (RTK)
Pathway is ALWAYS ON -> breast cancer
- oncogenic
- gain of function mutation
How do mutations in tumor suppressors lead to cancer?
- loss of function mutations
- need two defective copies of the gene (loss of heterozygosity)
- mutations in proteins that suppress the cell cycle
- p53
- p21
- RB (retinoblastoma) - sequesters EF2
- BRCA gene
What activates p53?
What inhibits p53?
ACTIVATION:
- phosphorylation activates/stabilizes it —> expression of p21
INHIBITION:
Mdm2 (ubiquitin-like protein) -> targets p53 for degradation
What increases cyclin concentrations?
What decreases it?
INCREASES
- expression of Myc (transcription factor)
DECREASES
cyclosomes “anaphase-promoting complexes” (APCs)
—> ubiquination -> degradation